儿童静脉血栓栓塞:里瓦洛克萨班的经验
Luca Spiezia1, Elena Campello1, Daniela Tormene1
1General Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University School of Medicine, Padova, Italy.
Seminars in thrombosis and hemostasis
|January 5, 2024
概括
儿科静脉血栓塞栓症 (VTE) 的管理具有挑战性. 利瓦罗克萨班口服悬浮为儿童提供安全有效的口服治疗选择,并得到了强有力的临床试验数据的支持.
科学领域:
- 儿科血液学 儿科血液学
- 药理学和治疗学 药理学和治疗学
- 临床试验研究 临床试验研究
背景情况:
- 儿科静脉血栓塞栓症 (VTE) 的发生率显著增加.
- 目前儿童的静脉瘤治疗包括繁的腹腔药物和频繁的血液检查.
- 需要安全,有效和口服的抗凝血剂用于儿科.
研究的目的:
- 评估小儿患者里瓦洛克萨班口服悬浮剂的疗效和安全性.
- 通过使用药理动力学建模,为儿童制定适合的里瓦罗克萨班剂量表.
- 审查支持rivaroxaban在各种儿科VTE情景中的使用的临床证据.
主要方法:
- 开发一个基于生理学的药物动力学模型,包括儿科生长和成熟.
- 开展全面的研究计划,包括I,II和III期临床试验.
- 第三阶段EINSTEIN JUNIOR试验招募了500名儿科患者 (出生至<18岁).
主要成果:
- 里瓦罗克萨班的疗效和安全性表现与儿童群体中成年人研究相似.
- 确立了剂量方案,相当于成人20毫克剂量.
- 结果支持利瓦洛克萨班用于预防复发性静脉瘤和治疗儿童大出血.
结论:
- 里瓦罗克萨班口服悬浮是一种安全有效的口服治疗儿科静脉瘤.
- 临床证据支持其在多样化的儿科患者群体和血管床上使用.
- 里瓦罗克萨班在儿童中提供了一个有益的替代传统的肠道抗凝剂.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
702
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
702
Esophageal Varices-II: Clinical Features and Management
71
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
71
Disorders of Hemostasis
922
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
922
Esophageal Varices-I: Introduction
144
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
144
Overview of Systemic Veins
472
Systemic veins are crucial blood vessels that return deoxygenated blood from various body tissues back to the heart. There are three systemic veins that return deoxygenated blood to the heart, they are as follows.
The coronary sinus, the heart's principal vein, resides in the coronary sulcus on the heart's posterior aspect. This broad venous channel receives nearly all venous blood from the myocardium, the heart muscle. It is fed by three primary veins: the great cardiac vein, the...
The coronary sinus, the heart's principal vein, resides in the coronary sulcus on the heart's posterior aspect. This broad venous channel receives nearly all venous blood from the myocardium, the heart muscle. It is fed by three primary veins: the great cardiac vein, the...
472


